Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2CLIMB-02: tucatinib or placebo plus ado-trastuzumab emtansine in unresectable locally advanced or metastatic HER2-positive breast cancer
CTR20212619Phase 3Active
- Sponsor
- Seagen Inc.
- Start
- Jun 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tucatinib, trastuzumab emtansine in breast cancer, sponsored by Seagen Inc.. Started Jun 2022; status: active.
02
Drugs
tucatinibtrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20212619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212619.